However, problems with the prophylactic use of PSCZ include its high cost and strong CYP3A4 inhibitory effect, which has a significant impact on key drugs for GVHD prevention, such as CSP and TAC, which are frequently used in transplantations.23 The gene discussed is CYP3A4; the disease is graft versus host disease.